Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001-Reference-Cited by-同舟云学术

Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

Published:2015-03 Issue:3 Volume:10 Page:486-491
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ichihara Eiki,Hotta Katsuyuki,Nogami Naoyuki,Kuyama Shoichi,Kishino Daizo,Fujii Masanori,Kozuki Toshiyuki,Tabata Masahiro,Harada Daijiro,Chikamori Kenichi,Aoe Keisuke,Ueoka Hiroshi,Hosokawa Shinobu,Bessho Akihiro,Hisamoto-Sato Akiko,Kubo Toshio,Oze Isao,Takigawa Nagio,Tanimoto Mitsune,Kiura Katsuyuki

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference26 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

4. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial;Signal Transduction and Targeted Therapy;2024-08-13

2. Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer;Cancers;2024-06-12

3. A randomized phase II study of afatinib alone or combined with bevacizumab for treating chemo-naïve patients with non-small cell lung cancer harboring EGFR mutations;Lung Cancer;2023-10

4. A pilot study of anlotinib with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated EGFR-mutant patients with advanced non-small cell lung cancer;Translational Lung Cancer Research;2023-06

5. Nanotechnology – a robust tool for fighting the challenges of drug resistance in non-small cell lung cancer;Beilstein Journal of Nanotechnology;2023-02-22